Dembic Zlatko

Title: Dembic Zlatko: Innovator in TNF Receptor Research

Introduction

Dembic Zlatko is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the development of proteins that bind tumor necrosis factor (TNF). With a total of 2 patents, his work has implications for therapeutic applications in various diseases.

Latest Patents

Zlatko's latest patents include innovations related to the Human TNF receptor. The first patent focuses on non-soluble proteins and their fragments that bind TNF in homogeneous form. It also covers the physiologically compatible salts of these proteins, especially those with a molecular weight of about 55 or 75 kD under non-reducing SDS-PAGE conditions. This patent outlines a process for isolating such proteins, developing antibodies against them, and identifying DNA sequences that code for these proteins and their fragments.

The second patent, titled Human TNF receptor fusion protein, shares similar themes. It also addresses non-soluble proteins and their fragments that bind TNF, along with the processes for their isolation and the development of antibodies. This work emphasizes the importance of recombinant proteins and their manufacture using transformed pro- and eukaryotic host cells.

Career Highlights

Dembic Zlatko is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His research and innovations have contributed to the advancement of therapeutic strategies targeting TNF-related pathways.

Collaborations

Zlatko has collaborated with notable colleagues, including Manfred Brockhaus and Reiner Gentz. These partnerships have enhanced the scope and impact of his research in the field.

Conclusion

Dembic Zlatko's work in the development of TNF receptor-related proteins showcases his innovative spirit and dedication to advancing medical science. His contributions are vital for future therapeutic developments in treating diseases associated with TNF.